Overview

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD) receiving hemodialysis. Efficacy will be measured primarily by the change from baseline in hemoglobin (Hgb).
Phase:
Phase 3
Details
Lead Sponsor:
Rockwell Medical Technologies, Inc.
Treatments:
Dialysis Solutions
Iron